Dear Reader,
One question could save you thousands of dollars this year. I explain it fully right here, but let me give you the short version first...
I suggest you head down to your bank today and ask them:
"If I moved my money to Elon Musk's new bank, would I make more?"
The answer, right now, is almost certainly yes.
Elon's new banking platform is paying up to 15 times the national average interest rate, and insures deposits up to $250,000, just like a traditional bank.
Which means there's now a real, government-backed alternative to the 0.4% your bank has been getting away with paying you for years.
It's already moved $1 billion in a matter of days. (See exactly how it works, and how to get in, here.)
And it's just the first step in what Elon has openly said is his goal: to build "the biggest financial institution in the world."
My name is Luke Lango. I was voted America's #1 stock picker in 2020. My readers have had the chance to see gains as high as 13,500% with AMD, 5,000% with Nvidia, and 1,200% with Palantir.
But this isn't just a story about where to park your savings...
It's the first sign of a much bigger shift...one that could lead to huge gains for investors who position themselves early.
I've put together my full research on exactly how to do that on this page here.
Regards,
Luke Lango
Senior Investment Analyst, InvestorPlace
P.S. JPMorgan CEO Jamie Dimon, the most powerful banker in America, has already warned that banks should be "scared s**tless" about exactly this kind of disruption. Elon's new rate is 15X higher than what your bank pays you. My new research shows you both how to access it, and how to profit from the disruption Dimon himself saw coming. Everything you need to know is waiting for you on this page.
As Employers Drop Obesity Drug Coverage, Hims & Hers Could Be the Winner
Reported by Jessica Mitacek. Article Published: 7/6/2026.
Key Points
- Employers are expected to drop coverage for GLP-1 weight-loss drugs in 2027, potentially driving patients toward Hims & Hers Health's telehealth subscription platform.
- Hims & Hers shares have surged more than 45% in 30 days and about 160% since their February low, leaving the stock technically overbought.
- Wall Street remains largely cautious on HIMS, with a consensus Hold rating, rising short interest, and increased insider selling despite the stock's rally.
- Special Report: Forget SpaceX. Buy the company Musk can't replace.
The healthcare sector is one of the best-performing sectors in the S&P 500 over the past month, with a gain of about 6%. But while that rebound has been led by a handful of mega-cap Big Pharma companies, it has also shown up in the performance of smaller firms.
One of those is mid-cap Hims & Hers Health (NYSE: HIMS), the telehealth platform that provides direct-to-consumer (D2C) personal care products and virtual medical services.
BlackRock and JPMorgan are quietly buying - here's what they see (Ad)
Trump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money network by April 2027. BlackRock CEO Larry Fink already calls it 'the next major evolution in market infrastructure.'
Our research has identified one small, overlooked position at the center of this policy-driven shift - already drawing quiet institutional buying from BNY Mellon, State Street, and JPMorgan. It currently trades for pennies relative to where institutional demand could push it. The Q3 2026 compliance deadline may be the last window before prices move.
Click here to see the full research and the position nameOver the past 30 days, HIMS has gained more than 45%, bringing the stock’s year-to-date (YTD) increase to nearly 20%. After a run like that, the stock may be due for a short-term breather. But according to healthcare industry experts, a looming catalyst could have an outsized benefit on Hims & Hers in 2027 and beyond, setting the stock up as a buying opportunity on its next pullback.
The GLP-1 Craze Is Pushing Up Employers’ Healthcare Plan Costs
As the cost of weight-loss drugs continues to climb, Reuters recently reported that some employers are planning to drop coverage for GLP-1 treatments, including Wegovy, Ozempic, Zepbound, Mounjaro, and Foundayo—products manufactured by Novo Nordisk (NYSE: NVO) and Eli Lilly (NYSE: LLY).
Last year, more than 40% of employers covered weight-loss drugs, and estimates for this year are roughly the same. But analyses from two industry groups cited by Reuters suggest that could change in 2027.
According to the policy research group Business Group on Health, about 10% of employers that currently offer coverage for GLP-1 drugs for weight loss said they planned to drop them in 2027. A second survey from Mercer, a benefits consultancy, found that 5% of large employers plan to drop coverage in 2027 or are actively considering doing so.
While that is unfortunate news for those undergoing treatment, it is welcome news for HIMS shareholders. Patients losing healthcare coverage for GLP-1 drugs could be a boon for Hims & Hers Health, which currently generates around one-third of its revenue from its weight-loss business.
Analysts forecast the company’s revenue to grow from an estimated $2.89 billion in 2026 to $3.45 billion in 2027, and increased subscription demand for weight-loss drugs amid shrinking insurance coverage should play a significant role in that top-line growth.
Lost coverage for GLP-1 treatments should spur a migration to D2C telehealth providers, with Hims & Hers serving as a natural destination because its platform bundles medical provider access, unlimited clinical consultations, and pharmacy fulfillment services into one streamlined subscription.
Technical Analysis and Wall Street Suggest a Correction Is Ahead
With its recurring revenue model, Hims & Hers should be a long-term beneficiary of dropped coverage. The platform charges a $39 fee for the first month of its weight-loss membership. After that, the charge rises to $149 for clinical subscriptions, not including the cost of the medication itself. Medication is billed separately, and Hims says the membership does not include or guarantee a prescription. Compounded oral options, for instance, can run from $145 to more than $199 per month, while branded GLP-1 pens like Wegovy can cost even more.
However, after roughly a 160% gain from its YTD low on Feb. 27, HIMS appears overdue for a price correction. According to the Relative Strength Index (RSI)—a technical momentum indicator that shows whether a stock is overbought (above 70), oversold (below 30), or fairly valued (somewhere in between)—HIMS has moved into overbought territory.
As shown by the green arrow below, the RSI on HIMS’ one-year chart currently reads 70.86, suggesting that the stock is overbought and due for a price reversal:
Technical analysis is hardly a perfect science. But the last two times the stock’s RSI breached 70—first in mid-April and then again in mid-June—HIMS pulled back more than 28% and nearly 8%, respectively, before continuing its rally.
Meanwhile, Wall Street remains bearish on the stock after its outperformance this year. Of the 16 analysts currently covering HIMS, only four assign it a Buy rating.
Overall, the stock receives a consensus Hold rating alongside a 12-month price target that implies more than 19% potential downside from current prices.
Concerningly, with a high-volatility beta of 2.35, current short interest in HIMS now stands at more than 32% of the float, or about 65.4 million shares valued at $1.97 billion.
That is the most the stock has been shorted since March and marks a nearly 5% month-over-month increase.
At the same time, insider activity has seen an uptick in selling this year. In Q1 2026, $3.46 million worth of HIMS shares were sold with no buys. In Q2, that figure rose to $4.86 million sold against $1.17 million bought.
Sandisk: What the Chart Is Trying to Tell Us
Reported by Sam Quirke. Article Published: 7/17/2026.
Key Points
- SanDisk shares have fallen roughly 40% from their June 22 peak near $2,350, breaking below the key $1,500 support level and raising technical concerns.
- An analyst downgrade from Erste Group and volatile trading in SK Hynix's new IPO have added pressure on SanDisk and broader memory sector sentiment.
- Investors are watching SanDisk's August 5 earnings report for signs on NAND pricing trends, supply agreements, margins, and guidance to determine the stock's next direction.
- Special Report: Forget SpaceX. Buy the company Musk can't replace.
For most of the first half of the year, SanDisk Corporation (NASDAQ: SNDK) could seemingly do no wrong. The memory and storage giant was one of the market's most explosive performers, riding the wave of AI-driven demand to a series of fresh record highs.
However, something appears to have shifted over the past few weeks, and the chart is now flashing warning signs that investors would be wise to ignore at their own peril.
BlackRock and JPMorgan are quietly buying - here's what they see (Ad)
Trump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money network by April 2027. BlackRock CEO Larry Fink already calls it 'the next major evolution in market infrastructure.'
Our research has identified one small, overlooked position at the center of this policy-driven shift - already drawing quiet institutional buying from BNY Mellon, State Street, and JPMorgan. It currently trades for pennies relative to where institutional demand could push it. The Q3 2026 compliance deadline may be the last window before prices move.
Click here to see the full research and the position nameSince peaking near $2,350 on June 22, SanDisk has failed to make a new high. Worse still, it has started to form a pattern of lower highs and lower lows, the kind of technical structure that tends to make chart watchers nervous.
The stock is now trading below $1,500, in the $1,400s, after slicing through a level that had held firm for weeks—representing a drop of roughly 40% from its peak in just a few weeks. With earnings due in roughly three weeks, the question is whether the chart is signaling a healthy pause or a real breakdown.
The Levels That Matter Right Now
The most important line in the sand for SanDisk had been the $1,500 level. The stock bounced off it twice earlier this month, suggesting there were still buyers willing to step in and defend it. But each retest tends to weaken support rather than strengthen it, and $1,500 has now given way—a bearish development that shifts the focus to where the next floor may lie.
With $1,500 gone, the chart doesn't offer much of a safety net until around $1,300, the next major area of support. That's a meaningful further drop from current levels, and it's exactly the kind of air pocket that can open up when a key floor breaks and the remaining buyers step back to wait for lower prices.
On the flip side, bulls will argue that a stock that has risen as far and as fast as SanDisk has this year was always going to need to digest those gains at some point. A 40% pullback sounds dramatic, but in the context of the enormous run that preceded it, it can just as easily be viewed as a healthy reset rather than the start of something more sinister.
2 Fresh Catalysts Adding Pressure
This technical weakness hasn't developed in a vacuum, and two recent developments have added to the pressure. The first came last week, when Erste Group downgraded SanDisk from Buy to Hold. That's notable not just on its own terms, but because it's one of the first bearish analyst moves on the stock in months, after a long stretch in which the analyst community had been almost uniformly positive.
The second dynamic is more unusual. The record-breaking initial public offering from South Korea's SK Hynix Inc. (NASDAQ: SKHY) last week introduced a fresh variable into the memory space. Rather than lifting sentiment, the fact that SK Hynix shares have traded with extreme volatility in their opening sessions appears to be spooking U.S. investors in memory names like SanDisk.
The read-through is that if one of the world's largest memory players is struggling to hold its valuation out of the gate, it raises uncomfortable questions about how richly valued the entire sector may have become.
What to Watch for in the Earnings Report
With the technical picture quite finely balanced, SanDisk's August 5 earnings report has taken on added significance, and there are a few specific things investors should be watching closely. The most important is pricing. The entire bull case for SanDisk this year has rested on the strength of NAND pricing driven by AI-related demand, so any commentary suggesting that pricing momentum is slowing, or any weakness in average selling prices, would be a red flag.
Beyond pricing, investors should watch for updates on the company's longer-term supply agreements. SanDisk has been locking in multi-year deals that provide revenue visibility, and any new contract signings or expansions of existing ones would reinforce the argument that this is a structurally stronger business than the market is currently giving it credit for.
Margin trends and forward guidance will also be scrutinized heavily, particularly any commentary on how the company sees demand shaping up in the back half of the year.
Reading the Tea Leaves
So what is the chart actually trying to tell us? It’s hard to ignore the feeling that SanDisk is at a genuine inflection point right now, and the way the chart moves in the coming sessions will say a lot about how it could trade through the rest of the year.
The current downtrend isn't a great look, but it could also simply be some well-earned consolidation after a monster rally. With $1,500 now in the rearview mirror, the practical takeaway for investors is to watch that $1,300 level like a hawk in the coming sessions and let the earnings report do most of the talking next month.
This email communication is a sponsored message from InvestorPlace, a third-party advertiser of The Early Bird and MarketBeat.
This ad is sent on behalf of InvestorPlace Media at 1125 N. Charles Street, Baltimore, Maryland 21201. If you're not interested in this opportunity, please click here.
If you have questions about your subscription, don't hesitate to email MarketBeat's U.S. based support team at contact@marketbeat.com.
If you no longer wish to receive email from The Early Bird, you can unsubscribe.
© 2006-2026 MarketBeat Media, LLC.
345 N Reid Place #620, Sioux Falls, S.D. 57103-7078. United States..
No comments:
Post a Comment